Rating
Buy
Price target
$220
Previous
$275
Implied upside
+47%

Stifel analyst Brad Reback lowered the price target on Oracle (NYSE: ORCL) to $220.00 (from $275.00) while maintaining a Buy rating.

“Oracle is up ~9% AH, as Cloud revenue (~$8.9B, +41% Y/Y-CC) reached the high end of guidance, driven by AI infrastructure (+243% Y/Y) and Multi-cloud database (+531% Y/Y).

Given management’s commentary demand for these offerings outweighs supply, we expect accelerating revenue growth for these solutions to contribute to accelerating IaaS growth as additional DC-capacity/multi-cloud database regions come online in coming quarters.

EPS beat by ~5 cents on a lower tax rate/opex discipline as the GM of new AI capacity added in Q3 was ~32%, in-line with management’s target model (30-40%).

Looking forward, management reiterated the FY26 revenue guide (>$67B) and $50B of Capex, but raised the FY27 guide by $1B to $90B. We expect sustained CAPEX growth in FY27 ($75B).

Net/net, we believe that accelerating IaaS growth stemming from AI and multi-database cloud, and sustained momentum in SaaS apps, should lead to better EPS growth rates in FY27.”

Disclaimer
The price target and rating on this page are the opinion of the issuing research firm and its analyst, not of Price Target. This page is published for informational purposes only and is not investment advice, a recommendation, or an offer to buy or sell any security. Past performance does not guarantee future results. Consider your own circumstances and consult a licensed financial adviser before making investment decisions.

This research note is reproduced verbatim from the issuing firm. Price Target never edits, paraphrases or alters analysts’ words — we only republish them in one place.

Share

Share on
Price Target is an archive of Wall Street analyst research, published for informational purposes only. Nothing on this site is investment advice, a recommendation, or an offer to buy or sell any security. Analyst ratings and price targets are the opinions of the issuing firms, not of Price Target. Always do your own research or consult a licensed financial adviser.